News Focus
News Focus
Replies to #2161 on Biotech Values
icon url

DewDiligence

05/19/04 6:38 PM

#2233 RE: DewDiligence #2161

Small insider purchase:

http://www.sec.gov/Archives/edgar/data/880431/000088043104000029/xslF345X02/edgar.xml

Independent director Frank Ecock bought 10,000 shares at $3.53 yesterday, increasing his actual shares (excluding options) from 40K to 50K.

Although this is clearly not a large transaction, it’s nice to see an insider step up to the plate and buy shares with his own money. The reason for the purchase? Mr. Ecock probably thought the stock was too damn cheap.

icon url

DewDiligence

05/25/04 7:50 PM

#2278 RE: DewDiligence #2161

Osagie Imasogie buys $200K of GENR in open market:

GENR’s independent director Imasogie filed three SEC Form-4’s today (two of which appear to be duplicates). These filings show a purchase of 25,000 shares beginning on May 11 at an average price of $3.96, and a purchase of 26,150 shares beginning on May 14 at an average price of $3.73. Thus, Imasogie now owns 51,150 shares at an average price a little under $4/share. He also holds 20K options exercisable at $3.50 which were granted when Imasogie officially began his tenure on GENR’s B.O.D. in January.

(For GENR’s insider holdings excluding these purchases by Imasogie, please see: #msg-3069875.)

--
Recently, OXGN’s CEO and CSO bought $14-15K each of shares on the open market, which I criticized as token, cosmetic purchases. As a shareholder, Imasogie’s purchases of approximately $200K are much more to my liking!